CAM
BIVV

Capstone Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Capstone Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$975K Buy
16,201
+74
+0.5% +$4.21K 0.03% 595
2017
Q1 		$878K Buy
+16,127
New +$794K 0.02% 631

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Capstone Asset Management's BIVV Position: Q2 2017 in Review

Capstone Asset Management increased its Bioverativ Inc. Common Stock (BIVV) stake by 0.46% in Q2 2017, buying an estimated $4.21K and bringing the position to 16,201 shares worth $975K. The position accounts for 0.03% of the portfolio, ranked #595.

Capstone Asset Management first reported a position in BIVV in Q1 2017 and has held it in 2 quarters since. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Capstone Asset Management held 16,201 shares of Bioverativ Inc. Common Stock worth $975K as of Q2 2017.
  • Capstone Asset Management bought 74 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $4.21K.
  • Bioverativ Inc. Common Stock made up 0.03% of Capstone Asset Management's portfolio in Q2 2017, its #595 holding.
  • Capstone Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and has held it in 2 quarters since.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.